Should we Cryopreserve Allogenic Hematopoietic Stem Cell Grafts?
Ewa Bembnista, Patrycja Stawicka, Paula Matuszak, Anna Łojko-Dankowska, Dominik Dytfeld, Magdalena Matuszak, Anna Wache, Katarzyna Kaźmierska, Ewa Majewska, Krzysztof Lewandowski, Lidia Gil
Author Information
Ewa Bembnista: Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland; ewa.bembnista@skpp.edu.pl.
Patrycja Stawicka: Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
Paula Matuszak: Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
Anna Łojko-Dankowska: Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
Dominik Dytfeld: Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
Magdalena Matuszak: Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
Anna Wache: Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
Katarzyna Kaźmierska: Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
Ewa Majewska: Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
Krzysztof Lewandowski: Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
Lidia Gil: Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
BACKGROUND/AIM: Cryopreservation of allogeneic hematopoietic cells can be an necessary step in the preparation of a graft for transplantation. The purpose of this study was to evaluate the safety of cryopreservation of allogeneic hematopoietic cells and the clinical outcomes of patients who received a cryopreserved transplant. PATIENTS AND METHODS: The study included data from a comparative analysis conducted on a group of 100 patients diagnosed with acute myeloid leukemia who received cryopreserved (50 patients) and fresh (50 patients) transplants. Both quantitative and qualitative parameters of the grafts were evaluated, as well as the patients' hematopoietic recovery. RESULTS: Statistical analysis of the time to engraftment of neutrophils, nucleated cells, and platelets showed no differences between the group of patients who received cryopreserved transplants and those who received fresh transplants. A higher count of CD34+ cells in the graft significantly reduced the time required for patients to reach their reference values of neutrophils, nuclear cells, and platelets (<0.05). CONCLUSION: Cryopreservation of allogenic transplants should be reserved as an option when fresh grafts are not feasible for various reasons.
